NCT05207774

Pre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes Remission

Pre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes remissionPre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes Remission

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: Soroka University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in obese adults with diabetes undergoing bariatric surgery. Subjects will be randomized to receive of intranasal oxytocin or placebo (8 units 3 times daily) for 8 weeks prior surgery. Study visits include screening to determine eligibility, CGM will be connected before and after oxytocin administration, and 1 year post surgery. blood tests including oral glucose tolerance test will be done and fat samples will be taken during surgery. The investigator's hypothesis is that oxytocin administration prior bariatric surgery can induce diabetes remission in patients with diabetes

Conditions

• Obesity
• Diabetes
• Bariatric Surgery

Interventions

Type	Name	Description
DRUG	Oxytocin	8 weeks intranasal oxytocin 24 units per day. 8 units prior each meal. 4units/0.1 ml per puff
DRUG	placebo	8 weeks intranasal placebo 0.6 ml per day. . 0.1 ml per puff

Timeline

• Start date: 2020-01-09
• Primary completion: 2023-08-30
• Completion: 2025-08-30
• First posted: 2022-01-26
• Last updated: 2022-01-26

Locations

1 site across 1 country: Israel